2. Academic Validation
  3. KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer

KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer

  • Nat Commun. 2023 May 5;14(1):2602. doi: 10.1038/s41467-023-38097-1.
Jiawen Bu # 1,  Yixiao Zhang # 1,  Sijin Wu # 1 2,  Haonan Li # 3,  Lisha Sun # 1,  Yang Liu 4 5,  Xudong Zhu 1,  Xinbo Qiao 1,  Qingtian Ma 1,  Chao Liu 1,  Nan Niu 1,  Jinqi Xue 1,  Guanglei Chen 1,  Yongliang Yang 6 7,  Caigang Liu 8
Affiliations

Affiliations

  • 1 Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China.
  • 2 Shenzhen Jingtai Technology Co., Ltd. (XtalPi), International Biomedical Industrial Park (Phase II) 3F, 2 Hongliu Rd, Futian District, 16023, Shenzhen, China.
  • 3 School of Bioengineering, Dalian University of Technology, 116023, Dalian, China.
  • 4 School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, 110016, Shenyang, China.
  • 5 Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, 110016, Shenyang, China.
  • 6 Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China. everbright99@foxmail.com.
  • 7 School of Bioengineering, Dalian University of Technology, 116023, Dalian, China. everbright99@foxmail.com.
  • 8 Cancer Stem Cell and Translation Medicine Lab, Department of Oncology, Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shengjing Hospital of China Medical University, 110004, Shenyang, China. liucg@sj-hospital.org.
  • # Contributed equally.
PMID: 37147285 DOI: 10.1038/s41467-023-38097-1
Abstract

Failure to achieve complete elimination of triple negative breast Cancer (TNBC) stem cells after Adjuvant therapy is associated with poor outcomes. Aldehyde dehydrogenase 1 (ALDH1) is a marker of breast Cancer Stem Cells (BCSCs), and its enzymatic activity regulates tumor stemness. Identifying upstream targets to control ALDH+ cells may facilitate TNBC tumor suppression. Here, we show that KK-LC-1 determines the stemness of TNBC ALDH+ cells via binding with FAT1 and subsequently promoting its ubiquitination and degradation. This compromises the Hippo pathway and leads to nuclear translocation of YAP1 and ALDH1A1 transcription. These findings identify the KK-LC-1-FAT1-Hippo-ALDH1A1 pathway in TNBC ALDH+ cells as a therapeutic target. To reverse the malignancy due to KK-LC-1 expression, we employ a computational approach and discover Z839878730 (Z8) as an small-molecule inhibitor which may disrupt KK-LC-1 and FAT1 binding. We demonstrate that Z8 suppresses TNBC tumor growth via a mechanism that reactivates the Hippo pathway and decreases TNBC ALDH+ cell stemness and viability.

Figures
Products
Inhibitors & Agonists